

1 **Title:** Blood-based host biomarker diagnostics in active case finding for pulmonary
2 tuberculosis: a diagnostic case-control study

3 **Authors**

4 Flora Martinez Figueira Moreira, MS,¹ Renu Verma, PhD,² Paulo Cesar Pereira dos Santos,
5 BS,¹ Alessandra Leite, BS,¹ Andrea da Silva Santos, PhD,¹ Rafaele Carla Pivetta de Araujo,
6 MS,¹ Bruna Oliveira da Silva, BS,¹ Júlio Henrique Ferreira de Sá Queiroz, MS,¹ David H.
7 Persing, PhD,³ Erik Södersten, PhD,⁴ Devasena Gnanashanmugam, MD,⁵ Purvesh Khatri,
8 PhD,² Julio Croda, PhD,^{4,5,6,*} Jason R. Andrews, MD^{2,*}

9 **Affiliations**

- 10 1. Faculty of Health Sciences, Federal University of Grande Dourados, Dourados, MS,
11 Brazil
12 2. Stanford University School of Medicine, Stanford, CA, USA
13 3. Cepheid, Sunnyvale, CA, USA
14 4. Cepheid AB, Solna, Sweden
15 5. Oswaldo Cruz Foundation, Campo Grande, MS, Brazil
16 6. School of Medicine, Federal University of Mato Grosso do Sul, Campo Grande, MS,
17 Brazil
18 7. Yale School of Public Health, New Haven, CT, USA

19 *Contributed equally

20 **Correspondence**

21 Jason Andrews, MD
22 Division of Infectious Diseases and Geographic Medicine
23 Stanford University School of Medicine
24 Biomedical Innovations Building, Rm 3458
25 240 Pasteur Dr.
26 Stanford, CA 94305
27 Email: jandr@stanford.edu
28 Phone: +1 650 497 2679

29 **Abstract Word Count:** 279

30 **Word Count:** 3,594

31 **Tables:** 2

32 **Figures:** 5

33 **References:** 28

34 **Abstract**

35 **Background:** There is a need to identify scalable tuberculosis screening strategies among
36 high burden populations. The WHO has identified a non-sputum-based triage test as a
37 development priority.

38 **Methods:** We performed a diagnostic case-control study of point-of-care C-reactive protein
39 (CRP) and Xpert-MTB-Host-Response (Xpert-MTB-HR) assays in the context of a mass
40 screening program for tuberculosis in two prisons in Brazil. All incarcerated individuals
41 irrespective of symptoms were screened by sputum Xpert-MTB/RIF and sputum culture.
42 Among consecutive, Xpert-MTB/RIF or culture-confirmed cases and Xpert-MTB/RIF and
43 culture-negative controls, CRP was quantified in serum by a point-of-care assay (iChroma-
44 II) and a 3-gene expression score was quantified from whole blood using the Xpert-MTB-
45 HR cartridge. We evaluated receiver operating characteristic area under the curve (AUC)
46 and assessed specificity at 90% sensitivity and sensitivity at 70% specificity, consistent with
47 WHO target product profile (TPP) benchmarks.

48 **Findings:** Two hundred controls and 100 culture- or Xpert-positive tuberculosis cases were
49 included. Half of tuberculosis cases and 11% of controls reported any tuberculosis
50 symptoms. AUC for CRP was 0.79 (95% CI: 0.73-0.84) and for Xpert-MTB-HR was 0.84
51 (95% CI: 0.79-0.89). At 90% sensitivity, Xpert-MTB-HR had significantly higher
52 specificity (53.0%, 95% CI: 45.0-69.0%) than CRP (28.1%, 95% CI: 20.2-41.8%)
53 ($p=0.003$), both well below the TPP benchmark of 70%. Among individuals with medium
54 or high sputum Xpert semi-quantitative load, sensitivity (at 70% specificity) of CRP (90.3%,
55 95% CI: 74.2-98.0) and Xpert-MTB-HR (96.8%, 95% CI: 83.3-99.9%) was higher.

56 **Interpretation:** For active case finding in this high tuberculosis-burden setting, CRP and
57 Xpert-MTB-HR did not meet TPP benchmarks for a triage test. However, Xpert-MTB-HR
58 was highly sensitive in detecting individuals with medium or high sputum bacillary burden.

59 **Funding:** National Institutes of Health (R01 AI130058 and R01 AI149620) and Brazilian
60 National Council for Scientific and Technological Development (CNPq-404182/2019-4).

61 **Keywords:** tuberculosis; diagnostic; host response; biomarker; triage; active case finding

62 Introduction

63 Despite advances in its diagnosis and treatment, tuberculosis (TB) is still the leading cause
64 of death among infectious diseases worldwide. It is estimated that 10 million people
65 developed the disease and 1.4 million died from the infection in 2019.¹ Delays in diagnosis
66 of active TB contribute to ongoing transmission of infection and hinder the reduction of
67 disease burden. The World Health Organization's "End TB Strategy" proposed a set of
68 actions to reduce the global incidence of TB by 2035, among which are the development of
69 new efficient clinical tools for a fast and accurate diagnosis and systematic screening in
70 high-risk groups to contribute to early detection of the diseases.²⁻⁴

71 Timely detection and treatment of cases are central elements in the control of TB
72 transmission. This is particularly critical in high TB risk environments, such as prisons.
73 Globally, prisons consistently harbor a very high burden of TB, with rates that are often >30
74 times higher than those of local non-incarcerated communities.⁵ Overcrowding, insufficient
75 sanitation, poor ventilation and inadequate health care in prisons facilitate the spread and
76 persistence of TB and other infectious diseases in these environments. In Central and South
77 America, TB notifications in prisons have increased by 269% since 2000, driven primarily
78 by growth in the size of the incarcerated population.⁶ Recent studies in Brazil have
79 demonstrated that the prevalence of active TB among incarcerated individuals exceeds 3
80 900 cases per 100 000 persons, among the highest reported in the world.⁷ There is an urgent
81 need for more effective strategies for early case detection among high TB burden
82 populations.

83 One of major obstacles to early TB diagnosis is that most approaches depend upon testing
84 of sputum, which individuals with less advanced disease may not consistently produce. In
85 response to this challenge, the WHO has endorsed a target product profile (TPP) for a non-
86 sputum based triage test that achieves high sensitivity in screening for active TB.³ There has
87 been considerable effort undertaken to develop and validate blood-based biomarkers for TB,
88 many focusing upon host immune response markers, including metabolomic, proteomic and
89 transcriptomic signatures of disease.⁸ Sweeney and colleagues found that a score based on
90 three differentially expressed genes (*GBP5* [Guanylate Binding Protein 5], *DUSP3* [Dual
91 Specificity Protein Phosphatase 3] and *KLF2* [Kruppel-like factor 2]) had high accuracy as
92 a screening test for active TB across multiple published cohorts.⁹ This signature was
93 subsequently validated for diagnosis of TB and prediction of progression from infection to
94 disease in independent cohorts.¹⁰ Based on these findings, Cepheid (Sunnyvale, CA, EUA)
95 developed an assay on their Xpert platform, cartridge-based RT-PCR assay (Xpert-MTB-
96 HR) that quantifies the relative mRNA levels of these 3 genes in a whole blood sample. A
97 recent study demonstrated its potential in triage and diagnosis of active TB among people
98 living with HIV and presenting to healthcare facilities with TB symptoms.¹¹ Whether this
99 assay would perform well for active case finding, in which individuals are proactively
100 screened for tuberculosis irrespective of symptoms, in a low HIV prevalence setting is
101 unknown. To address this knowledge gap, we performed a diagnostic case-control study
102 nested within a prospective active TB case finding study in prisons, evaluating the accuracy
103 of a blood based 3-gene signature assay as potential in triage and diagnosis of active TB.

104 **Methods**

105 *Study design and participants*

106 This nested diagnostic case-control study was part of larger prospective mass TB screening
107 study conducted in two male prisons (Estabelecimento Penal Jair Ferreira de Carvalho
108 [EPJFC] and Penitenciaria Estadual de Dourados [PED] in Mato Grosso do Sul, Brazil.⁷
109 Between April 2018 and May 2020, we recruited all incarcerated individuals ages ≥ 18 years
110 at both study prisons for TB screening irrespective of symptoms. After obtaining informed
111 consent, we administered a standardized questionnaire to collect demographic and clinical
112 information, including TB related symptoms as defined by WHO guidelines.¹² The selection
113 criteria for this study were the collection one spot sputum sample at enrollment and
114 availability of a whole-blood sample. For this nested case-control study, we included
115 consecutive participants who met case and control definitions (as described below) and had
116 serum and PAXgene-preserved whole blood available. We did not exclude individuals with
117 HIV or prior tuberculosis. Cases and controls were selected based on meeting outcome
118 definitions and prior to performing the diagnostic assays under investigation in this study.

119 *Laboratory procedures*

120 All participants were instructed to produce a sputum sample with a target volume of at least
121 2 mL. Sputum samples were tested at study entry by Xpert MTB/RIF G4 (prior to January,
122 2020) or Xpert Ultra (after January, 2020; Cepheid, Sunnyvale, CA, USA) along with
123 culture on Ogawa-Kudoh media. *M. tuberculosis* was confirmed from culture growth by an
124 immunochromatographic assay (TB Ag MPT64 Rapid Test, Standard Diagnostics, Seoul,
125 South Korea). Upon diagnosis of a case by positive sputum Xpert or culture, we collected
126 venous blood samples in PAXgene RNA tubes (Becton Dickinson, Franklin Lakes, USA) to
127 preserve RNA and in BD Vacutainer tubes (Becton Dickinson, Franklin Lakes, USA) to
128 obtain serum. We similarly collected blood from consecutive, Xpert-negative participants
129 as potential controls and performed QuantiFERON-TB Gold Plus assays (Qiagen, Hilden,
130 Germany) according to the manufacturer's instructions. We stopped control recruitment
131 upon identifying 200 Xpert negative individuals with valid QuantiFERON results. PAXgene
132 tubes and serum samples were all collected within 14 days of first sputum sample collection
133 (92% on same day) and were preserved in temperature-controlled freezers at -80°C from
134 collection until testing. C-reactive protein (CRP) concentrations were measured on serum
135 samples with a point-of-care assay (iChromaTM II, Boditech, South Korea), which has a
136 dynamic range of 2.5-300 mg/L. The cartridge-based RT-PCR assay (Xpert-MTB-HR) was
137 performed using 380 μL of PAXgene-preserved whole blood. The aliquot was centrifuged,
138 supernatant decanted, and pellet was resuspended in a lysis buffer and vortexed before
139 transfer to the Xpert-MTB-HR cartridge. The samples then were analyzed on a GeneXpert
140 machine, which generates a TB-score calculated from cycle threshold values for the 3-genes
141 according to the formula developed by Sweeney and colleagues.¹⁰ When using PCR-based
142 measurement technology, lower scores by this method have been associated with TB
143 disease. Sample preparation time was 15 minutes and GeneXpert run time was 50 minutes.
144 All participants were administered a rapid HIV test and evaluated through a nursing and
145 medical examination.

146 *Outcome Definitions*

147 We followed national Brazilian guidelines and WHO definitions for TB diagnosis. We
148 defined a microbiologically confirmed TB case as any individual with a positive sputum
149 Xpert MTB/RIF or sputum culture. Non-microbiologically confirmed (clinically defined)
150 TB cases were not available for inclusion in this study. Controls were defined as individuals
151 with negative sputum Xpert MTB/RIF and culture, who were clinically evaluated and not

152 believed to have active TB disease. All controls had been previously screened within the
153 past year and had a chest x-ray score by CAD4TB < 60. Additionally, we searched the state
154 Sistema de Informação de Agravos de Notificação (SINAN) data, in which all tuberculosis
155 cases are reported, for six months following enrollment to determine whether any of the
156 control participants were subsequently diagnosed with TB. QFT-Plus results were
157 interpreted as positive when IFN- γ concentration in the *M. tuberculosis* (*Mtb*) antigen tube
158 was ≥ 0.35 IU/mL as defined by the manufacturer.

159 *Statistical analysis*

160 We compared Xpert-MTB-HR scores and serum CRP concentrations between
161 microbiologically confirmed TB cases and controls, using Wilcoxon sign rank tests for
162 paired samples. We evaluated the linear correlation between Xpert-MTB-HR and CRP
163 concentrations among cases and controls. For CRP in linear analyses, values less than 2.5
164 mg/L (the lower limit of the reporting range) were set as 2.5 mg/L. We also compared Xpert-
165 MTB-HR scores and serum CRP concentrations among cases with controls stratified by
166 QFT-Plus positivity status. We calculated the receiver operating characteristic (ROC) area
167 under the curve (AUC) comparing TB cases and controls for Xpert-MTB-HR and CRP. We
168 compared AUC using DeLong's test. To evaluate performance at WHO benchmarks, we
169 calculated specificity at 90% sensitivity, and sensitivity at 70% specificity, along with 95%
170 confidence intervals. We further investigated the sensitivity according to Xpert MTB/RIF
171 cycle threshold (Ct) value and semi-quantitative load from sputum samples. This analysis
172 was restricted to cases identified by Xpert MTB/RIF G4, as semiquantitative results and
173 cycle thresholds are different for Xpert Ultra. We examined sensitivity for Xpert MTB/RIF
174 Ct under 28.0, a threshold identified by a recent multi-country study as being 95% sensitive
175 and 54% specific for smear positivity.¹³ We selected a sample size of 100 cases and 200
176 controls to achieve precision in 95% confidence interval of < +/- 6.5% for the expected
177 sensitivity of 90% and specificity of 70%. All analyses were performed using R, and ROC
178 analyses were performed using the pROC package.¹⁴

179 *Ethical considerations*

180 All participants in the study provided informed consent. This study was approved by Federal
181 University of Grande Dourados, the National Committee on Research Ethics
182 (#44997115.1.0000.5160 and #2.195.047), and the Institutional Review Board and Stanford
183 University (#40285). This study conforms to the Standards for Reporting of Diagnostic
184 Accuracy Studies (STARD) reporting guideline.¹⁵

185 *Role of the funding source*

186 The funders of the study had no role in study design, data collection, data analysis, data
187 interpretation, or writing of the report. The corresponding authors had full access to all the
188 data in the study and had final responsibility for the decision to submit for publication.

189 Results

190 Between April, 2018 and May, 2020, we screened 4,250 incarcerated individuals in two
191 prisons, of whom 1,751 were able to provide sputum for testing. Among these, 131 were
192 positive by sputum Xpert or culture, 1456 were negative by sputum Xpert and culture, and
193 129 were not positive but lacked one of the two assays due to insufficient sputum volume
194 (**Figure 1**). From these, we selected consecutive patients for whom baseline serum and
195 PAXgene RNA samples were available and included 100 individuals with microbiologically
196 confirmed TB and 200 individuals who were negative for TB by sputum Xpert MTB/RIF,
197 culture, and clinical evaluation and had valid QuantiFERON results.

198 Among the 100 TB cases, Xpert MTB/RIF results were available for 96, and 93 (97%) were
199 positive (85 by Xpert G4 [before January, 2020]; 8 by Xpert Ultra [after January, 2020]).
200 Seven cases were identified by culture only (four lacked Xpert results and three were Xpert
201 negative). All participants were men who were incarcerated at the time of enrollment, and
202 the median age was slightly younger among TB cases (median age: 31 years, IQR 25, 37)
203 compared with controls (median age: 34 years, IQR 28, 39). A lower proportion of cases
204 self-identified as Indigenous (7% vs 17%; $p=0.028$). TB cases were more likely to report
205 illicit drug use in the past year (80% vs 50%, $p<0.0001$), previous incarceration (87 vs 54%,
206 $p<0.0001$), and a known TB contact (82% vs 53%, $p<0.0001$). Overall, half of TB cases
207 reported any WHO TB symptom, compared with only 11% of controls ($p<0.0001$). The
208 most common symptom was cough, reported by 45% of cases and 10% of controls. Four
209 individuals with active TB (4%) were HIV co-infected, compared with none of the controls.
210 Among controls, 92 (46%) were QFT-Plus positive (**Table 1**). Ninety-two percent (276/300)
211 of serum and PAXgene RNA samples were collected on the same day as the first sputum
212 sample collection and 98% (293/300) were collected within 7 days.

213 Compared with controls, TB cases had higher CRP values (9.39 vs <2.5 mg/L; $p<0.0001$)
214 and lower Xpert-MTB-HR scores (1.69 vs 2.72; $p<0.0001$) (**Figure 2**). CRP and Xpert-
215 MTB-HR values were negatively correlated (spearman's $\rho = -0.44$, $p<0.0001$), and the
216 correlation was much stronger among TB cases ($\rho = -0.68$, $p<0.0001$) than controls ($\rho =$
217 0.01 , $p=0.874$) (**Figure 3**). Area under the curve in distinguishing TB cases from controls
218 was non-significantly higher for Xpert-MTB-HR (0.84, 95% CI: 0.79-0.89) than for CRP
219 (AUC 0.79, 95% CI: 0.73-0.84; p -value for ROC comparison = 0.105) (**Figure 4**). At 90%
220 sensitivity, the specificity of CRP was 28.1% (95% CI: 20.2-41.8%) and the specificity of
221 Xpert-MTB-HR was 53.0% (33.5-67.0%) (p -value for comparison, 0.003). At 70%
222 specificity, the sensitivity of CRP was 73% (95% CI: 62.1%-82.3%) and sensitivity of
223 Xpert-MTB-HR was 81% (95% CI: 72.0-89.0%) (p -value for comparison, 0.074)
224 (**Appendix Figure A1**).

225 Among TB cases, CRP and Xpert-MTB-HR values correlated with sputum semi-
226 quantitative Xpert MTB/RIF G4 values, which are based on PCR cycle thresholds.
227 Compared with TB cases with “very low” MTB quantities, those with “medium” or “high”
228 quantities had higher CRP (median: 20.4 vs <2.5 mg/L; $p<0.0001$) and lower Xpert-MTB-
229 HR scores (median: 1.06 vs 2.20; $p<0.0001$) (**Figure 5a**). At the WHO TPP specificity
230 target of 70%, the sensitivities of CRP and Xpert-MTB-HR were strongly correlated with
231 sputum semi-quantitative Xpert MTB/RIF values (**Table 2**). Among 29 individuals with
232 negative or very low semi-quantitative loads, CRP sensitivity was 44.8% and Xpert-MTB-
233 HR sensitivity was 69.0% (p -value for comparison, 0.111), whereas among the 31
234 individuals with medium or high semiquantitative loads, CRP sensitivity was 90.3% and
235 Xpert-MTB-HR sensitivity was 96.8% (p -value, 0.612). CRP (spearman's ρ , -0.57;
236 $p<0.0001$) and Xpert-MTB-HR (spearman's ρ , 0.54, $p<0.0001$) values also correlated
237 with sputum Xpert MTB/RIF Ct values (**Figure 5b**). Among 57 participants with sputum

238 Xpert MTB/RIF Ct < 28·0, sensitivity of CRP (at 70% specificity) was 81·3% and sensitivity
239 of Xpert-MTB-HR was 89·1%.

240 CRP and Xpert-MTB-HR scores did not differ among TB cases with and without symptoms
241 (p=0·541 for CRP; p=0·893 for Xpert MTB-HR). Among controls, CRP and Xpert-MTB-
242 HR values did not differ by QFT-Plus status (p=0·211 for CRP; p=0·802 for Xpert-MTB-
243 HR). We did not identify differences in AUC among any demographic and clinical
244 subgroups.

245 Discussion

246 Active case finding through systematic screening can be an effective means for early
247 detection of TB in high-risk populations, preventing onward transmission. However,
248 performing active case finding effectively and efficiently poses challenges, as diagnostics
249 may not perform well in individuals who have less advanced disease, fewer symptoms, and
250 may be unable to provide adequate sputum samples. To address this need, a target product
251 profile was developed for a non-sputum-based triage test that could achieve high sensitivity
252 (>90%) to identify individuals for further diagnostic evaluation.³ We tested two candidate
253 triage diagnostics—point-of-care CRP and a new gene expression based rapid molecular
254 diagnostic—from blood samples collected during systematic mass screening for TB
255 conducted in two high TB-burden prisons, where we recently reported active TB prevalence
256 of 3 900 per 100 000.⁷ We found that both diagnostics had moderate accuracy in
257 distinguishing microbiologically confirmed cases from controls, with Xpert-MTB-HR
258 achieving higher overall accuracy than CRP. At 90% sensitivity, specificity of Xpert-MTB-
259 HR was 53%, the latter falling below the target of 70%. However, both diagnostics had
260 greater sensitivity among individuals with higher MTB burden as measured by Xpert
261 MTB/RIF semi-quantitative load in sputum, suggesting that they may identify individuals
262 with greatest potential for transmission.

263 A number of studies have evaluated gene expression signatures for identifying individuals
264 with active or incipient TB.^{16–19} However, there have been few studies investigating
265 performance of these biomarkers in active case finding irrespective of symptoms, and these
266 earlier studies used laboratory-based assays rather than rapid molecular diagnostics.¹⁰ The
267 Xpert-MTB-HR test was implemented in a closed system cartridge that quantifies the
268 relative mRNA levels of 3 genes in a whole blood sample. Our results corroborate a previous
269 study conducted by Södersten and colleagues in a very different population and clinical
270 setting—screening HIV-infected individuals presenting with TB symptoms to clinics in
271 South Africa and Peru—which demonstrated feasibility of measuring the 3-gene signature
272 on this platform.¹¹ Consistent with this and earlier studies on the 3-gene signature, we found
273 that TB cases had lower Xpert-MTB-HR scores, indicating higher expression levels (up-
274 regulation) of *GBP5* and *DUSP3* compared with *KLF2*, compared with controls.^{9–11,20} The
275 AUC in this study (0.84) was lower than that reported by Södersten (0.94 against sputum
276 Xpert MTB/RIF),¹¹ but consistent with a previous smaller evaluation of the 3-gene signature
277 by laboratory-based qRT-PCR in this low HIV-prevalence, actively screened population
278 (0.87).¹⁰

279 Earlier studies have also investigated CRP testing for distinguishing individuals with active
280 TB from those without disease. High accuracy has been reported in some studies of HIV co-
281 infected patients,^{21,22} though there have been fewer studies assessing screening among HIV-
282 negative individuals, and performance has generally been poorer. A recent study among
283 HIV-negative inpatients in Uganda found specificity of 21% at sensitivity of 91%.²³ We are
284 unaware of any studies assessing C-reactive protein in the context of mass screening for
285 active case detection. We found the AUC to be 0.79 for the point-of-care CRP test in our
286 study, consistent with the moderate accuracy previously reported in HIV-uninfected
287 individuals. Notably, even among TB cases, the median CRP in our study was substantially
288 lower (9.39 mg/L) than that reported among HIV-infected TB patients in a two previous
289 studies (32.0 mg/L and 51.3 mg/L) by Yoon et al, which used the same device on serum and
290 whole blood samples, respectively.^{21,24} Our findings may indicate that HIV-negative
291 individuals have less systemic inflammation in the setting of TB, perhaps consistent with
292 the observation that HIV-infected individuals are more likely to have disseminated disease.²⁵

293 Neither of the two diagnostics evaluated met the published TPP benchmarks for a non-
294 sputum-based diagnostic (>90% sensitivity and >70% specificity);³ however, the Xpert-
295 MTB-HR performed better (specificity 53% vs 28%). Both assays performed well in
296 identifying individuals with medium or high *Mtb* semiquantitative load in sputum. At
297 specificity of 70%, CRP identified 90% (28/31) and Xpert-MTB-HR identified 97% (30/31)
298 patients with medium/high *Mtb* semiquantitative sputum Xpert® MTB/RIF result. Sputum
299 Xpert Ct values and semi-quantitative load have been shown to correlate with sputum smear,
300¹³ which in turn has been shown in multiple studies to predict infectiousness.^{26,27} It is thereby
301 conceivable that both of these diagnostics can reliably identify individuals who have high
302 bacillary burden and are more likely to transmit infection. Further studies are needed to
303 investigate whether these markers indeed identify these high transmission risk individuals,
304 and whether a triage test that identifies such individuals would be useful. Given that Xpert-
305 MTB-HR had lower accuracy in this setting than sputum Xpert® MTB/RIF, for it to be
306 impactful and cost-effective, it would need to either be lower cost or identify individuals
307 with incipient, extrapulmonary or sputum-negative TB in order to be cost-effective.

308 This study should be interpreted within the context of several limitations. First, all
309 participants were adult men. Our mass screening is focused in male prisons, as only two TB
310 cases were reported in the past year in female prisons, and our prior studies in female prisons
311 demonstrated a very low prevalence of TB in this state.²⁸ The absence of female
312 representation may have reduced the effects of confounding conditions like connective
313 tissue disorders and pregnancy, both of which can lead to CRP elevation. Second, control
314 participants all had chest radiographs with CAD4TB scores <60 one year prior, but this may
315 have led to selection of controls with less lung pathology, limiting generalizability.
316 However, >80% of all individuals in the study prisons have CAD4TB scores <60,⁷
317 suggesting that this group was still representative of the prison population. Third, because
318 this was done within the context of an ongoing mass screening program, we used an older
319 version of Xpert (G4) for the first part of the study and switched to the more sensitive Xpert
320 Ultra when it became available at the site in January, 2020; because the Ct values are not
321 comparable between the two cartridges, we only analyzed them for G4, which comprised
322 91% of the positive Xpert tests. Laboratory staff performing the biomarker diagnostics were
323 not blinded to the reference diagnostics, introducing potential for bias, though both
324 diagnostics have digital readouts and we retained electronic source files for the Xpert-MTB-
325 HR performance. This was a retrospective case-control study nested within a prospective
326 mass screening study, and it is possible that there was bias in selection of participants.
327 Additionally, there could have been reporting biases of symptoms and characteristics by
328 participants. Finally, we used Xpert and culture as the reference standards for classifying
329 cases and controls. It possible that the reference assays were false positives, though they
330 have very high specificity for tuberculosis. Some of the individuals classified as controls
331 may had subclinical or incipient TB that was not detected by sputum Xpert MTB/RIF or
332 culture; we performed one sputum Xpert MTB/RIF and culture on solid media. Using liquid
333 media for culture, performing multiple Xpert tests or cultures, or use of PET-CT could
334 improve classification. However, we note that all treated TB cases in this setting are
335 mandatorily reported in an electronic database, which we reviewed six months after
336 screening; none of the controls were diagnosed with TB in the six months following
337 screening. This reduces the risk that controls were misclassified. Further, misclassification
338 would likely bias differences in the biomarker diagnostics towards the null, meaning their
339 accuracy would be underestimated.

340 There is an urgent need for accurate, rapid tools for screening individuals at high risk of
341 tuberculosis, in order to focus further diagnostic testing and investigations. While Xpert
342 MTB-HR outperformed CRP testing in the context of mass screening in a low HIV-

343 prevalence population, it did not meet the WHO target product profile benchmarks for a
344 triage test. These findings may be related to the spectrum of disease observed in this setting.
345 Most TB cases in this population had low bacillary burden in their sputum, and half had no
346 symptoms at the time diagnosis, suggesting that mass screening identified them early in their
347 disease course, when they had less systemic inflammation. Among TB cases with medium
348 or high bacillary burden, Xpert-MTB-HR achieved >96% sensitivity at 70% specificity,
349 indicating that it may identify individuals with greater burden of infection and who might
350 be more infectious. Further studies are needed to evaluate its performance for active case
351 finding in other populations, and to determine whether it could be useful for averting
352 transmission in high-risk settings.

353 **Authors' contributions**

354 FM, RV, JC and JA designed the study. FM, PCPdS, AL, AdSS, RCPdA, BOdS, JHFdSQ
355 collected the data. FM and JA analyzed the data. ES, DG, and DHP developed the diagnostic
356 assay and provided training for its use prior to study commencement; they played no role in
357 assay performance for study samples and did not have access to study data. RV, DHP, ES,
358 DG, PK and JC assisted with interpretation of the completed analyses. FM and JA wrote the
359 first draft of the manuscript. All authors critically revised and approved the manuscript.

360 **Declaration of Interest**

361 JRA received grants from the U.S. National Institutes of Health to support this research. PK
362 is a co-inventor on a 3-gene TB score pending patent owned by Stanford University, which
363 has been licensed for commercialization. PK is a consultant with Cepheid. DHP, ES, and
364 DG are employed by Cepheid. Xpert-MTB-HR cartridges were provided by Cepheid.
365 Cepheid had no role in selection of participants, assay performance and interpretation, or
366 data analysis, and did not have access to the study results until all analyses were completed.

367 **Funding**

368 This study was approved by National Institutes of Health (R01 AI130058 and R01
369 AI149620) and Brazilian National Council for Scientific and Technological Development
370 (CNPq-404182/2019-4).

371 **Data sharing**

372 De-identified data will be made available by the corresponding author upon request.

373 **References**

- 374 1 World Health Organization. Global Tuberculosis Report 2020. Geneva, 2020
375 https://www.who.int/tb/publications/global_report/en/.
- 376 2 World Health Organization. The End TB Strategy. Geneva, 2014
377 https://www.who.int/tb/strategy/End_TB_Strategy.pdf?ua=1.
- 378 3 World Health Organization. High-priority target product profiles for new
379 tuberculosis diagnostics: report of a consensus meeting. 2014
380 [https://apps.who.int/iris/bitstream/handle/10665/135617/WHO_HTM_TB_2014.18](https://apps.who.int/iris/bitstream/handle/10665/135617/WHO_HTM_TB_2014.18_eng.pdf?sequence=1)
381 [_eng.pdf?sequence=1](https://apps.who.int/iris/bitstream/handle/10665/135617/WHO_HTM_TB_2014.18_eng.pdf?sequence=1).
- 382 4 World Health Organization. Systematic screening for active tuberculosis: an
383 operational guide. Geneva: World Health Organization, 2015
384 <https://apps.who.int/iris/handle/10665/181164>.
- 385 5 Baussano I, Williams BG, Nunn P, Beggiato M, Fedeli U, Scano F. Tuberculosis
386 incidence in prisons: a systematic review. *PLoS Med* 2010; **7**: e1000381.
- 387 6 Walter K, Martinez L, Arakaki-Sanchez, *et al*. The escalating tuberculosis crisis in
388 Central and South American prisons. In press. *Lancet* 2020.
- 389 7 Santos A da S, Oliveira RD de, Lemos EF, *et al*. Yield, Efficiency and Costs of
390 Mass Screening Algorithms for Tuberculosis in Brazilian Prisons. *Clin Infect Dis*
391 2020; : 1–29.
- 392 8 MacLean E, Broger T, Yerlikaya S, Fernandez-Carballo BL, Pai M, Denkinger CM.
393 A systematic review of biomarkers to detect active tuberculosis. *Nat Microbiol*
394 2019; **4**: 748–58.
- 395 9 Sweeney TE, Braviak L, Tato CM, Khatri P. Genome-wide expression for diagnosis
396 of pulmonary tuberculosis: a multicohort analysis. *Lancet Respir Med* 2016; **4**: 213–
397 24.
- 398 10 Warsinske HC, Rao AM, Moreira FMF, *et al*. Assessment of Validity of a Blood-
399 Based 3-Gene Signature Score for Progression and Diagnosis of Tuberculosis,
400 Disease Severity, and Treatment Response. *JAMA Netw Open* 2018; **1**: e183779.
- 401 11 Södersten E, Ongarello S, Mantsoki A, *et al*. Diagnostic accuracy study of a novel
402 blood-based assay # for identification of TB in people living with HIV. *J Clin*
403 *Microbiol* 2020; : JCM.01643-20.
- 404 12 Bone A, Aerts A, Grzemska M, *et al*. Tuberculosis control in prisons : a manual for
405 programme managers. <https://apps.who.int/iris/handle/10665/66823>.
- 406 13 Beynon F, Theron G, Respeito D, *et al*. Correlation of Xpert MTB/RIF with
407 measures to assess Mycobacterium tuberculosis bacillary burden in high HIV
408 burden areas of Southern Africa. *Sci Rep* 2018; **8**: 5201.
- 409 14 Robin X, Turck N, Hainard A, *et al*. pROC: an open-source package for R and S+ to
410 analyze and compare ROC curves. *BMC Bioinformatics* 2011; **12**: 77.
- 411 15 Bossuyt PM, Reitsma JB, Bruns DE, *et al*. STARD 2015: an updated list of
412 essential items for reporting diagnostic accuracy studies. *BMJ* 2015; **351**: h5527.
- 413 16 Zak DE, Penn-Nicholson A, Scriba TJ, *et al*. A blood RNA signature for
414 tuberculosis disease risk: a prospective cohort study. *Lancet* 2016; **387**: 2312–22.
- 415 17 Suliman S, Thompson EG, Sutherland J, *et al*. Four-Gene Pan-African Blood
416 Signature Predicts Progression to Tuberculosis. *Am J Respir Crit Care Med* 2018;
417 **197**: 1198–208.
- 418 18 Warsinske H, Vashisht R, Khatri P. Host-response-based gene signatures for
419 tuberculosis diagnosis: A systematic comparison of 16 signatures. *PLOS Med* 2019;
420 **16**: e1002786.
- 421 19 Gupta RK, Turner CT, Venturini C, *et al*. Concise whole blood transcriptional
422 signatures for incipient tuberculosis: a systematic review and patient-level pooled

423 meta-analysis. *Lancet Respir Med* 2020; **482**: 1–28.
424 20 Francisco NM, Fang Y-M, Ding L, *et al.* Diagnostic accuracy of a selected signature
425 gene set that discriminates active pulmonary tuberculosis and other pulmonary
426 diseases. *J Infect* 2017; **75**: 499–510.
427 21 Yoon C, Semitala FC, Atuhumuza E, *et al.* Point-of-care C-reactive protein-based
428 tuberculosis screening for people living with HIV: a diagnostic accuracy study.
429 *Lancet Infect Dis* 2017; **17**: 1285–92.
430 22 Yoon C, Semitala FC, Asege L, *et al.* Yield and Efficiency of Novel Intensified
431 Tuberculosis Case-Finding Algorithms for People Living with HIV. *Am J Respir*
432 *Crit Care Med* 2019; **199**: 643–50.
433 23 Meyer AJ, Ochom E, Turimumahoro P, *et al.* C-Reactive Protein for Active
434 Tuberculosis Among Inpatients without HIV in Uganda: A Diagnostic Accuracy
435 Study. *J Clin Microbiol* 2020; : JCM.02162-20.
436 24 Yoon C, Davis JL, Huang L, *et al.* Point-of-Care C-Reactive Protein Testing to
437 Facilitate Implementation of Isoniazid Preventive Therapy for People Living With
438 HIV. *JAIDS J Acquir Immune Defic Syndr* 2014; **65**: 551–6.
439 25 Mihret A, Abebe M, Bekele Y, Aseffa A, Walzl G, Howe R. Impact of HIV co-
440 infection on plasma level of cytokines and chemokines of pulmonary tuberculosis
441 patients. *BMC Infect Dis* 2014; **14**: 125.
442 26 Behr M, Warren S, Salamon H, *et al.* Transmission of Mycobacterium tuberculosis
443 from patients smear-negative for acid-fast bacilli. *Lancet* 1999; **353**: 444–9.
444 27 Hernandez-Garduno E. Transmission of tuberculosis from smear negative patients:
445 a molecular epidemiology study. *Thorax* 2004; **59**: 286–90.
446 28 Carbone A da SS, Paião DSG, Sgarbi RVE, *et al.* Active and latent tuberculosis in
447 Brazilian correctional facilities: a cross-sectional study. *BMC Infect Dis* 2015; **15**:
448 24.
449

450 **Tables**

451 **Table 1. Sociodemographic and clinical characteristics of incarcerated individuals with and without TB.**

| Variables | Total N=300 (%) | TB cases N=100 (%) | No TB N=200 (%) | p value |
|-------------------------------------|--------------------|-----------------------|--------------------|---------|
| Median age [IQR] | 33 [27, 38] | 31 [25, 37] | 34 [28, 39] | 0.0005 |
| Ethnicity | | | | |
| Mixed | 155 (52) | 50 (50) | 105 (52) | 0.7141 |
| White | 63 (21) | 24 (24) | 39 (20) | 0.3709 |
| Black | 39 (13) | 17 (17) | 22 (11) | 0.1498 |
| Indigenous | 41 (14) | 7 (7) | 34 (17) | 0.0198 |
| Asian | 2 (1) | 2 (2) | 0 | 0.1104 |
| Less than 8 years of schooling | 225 (75) | 75 (75) | 150 (75) | 1 |
| Current smoker | 190 (63) | 71 (71) | 119 (59) | 0.0571 |
| Illicit drug use over the last year | 180 (60) | 80 (80) | 100 (50) | <0.0001 |
| BCG vaccination scar | 255 (85) | 84 (84) | 171 (85) | 0.7341 |
| Previous TB | 23 (7) | 11 (11) | 12 (6) | <0.0001 |
| Know someone with TB | 189 (63) | 82 (82) | 107 (53) | <0.0001 |
| Report any WHO TB symptoms | 73 (24) | 50 (50) | 23 (11) | <0.0001 |
| Report cough | 66 (22) | 45 (45) | 21 (10) | <0.0001 |
| Previously incarcerated | 196 (65) | 87 (87) | 109 (54) | <0.0001 |
| HIV positive | 4 (1) | 4 (4) | 0 | 0.0118 |
| QuantiFERON positive | 92/200 (46) | NA | 92/200 (46) | .. |

452 IQR, Interquartile range. BCG, Bacillus Calmette-Guérin. TB, tuberculosis. WHO, World Health
453 Organization.

454 **Table 2. Sensitivity of C-reactive protein and Xpert-MTB-HR according to sputum Xpert MTB/RIF**
455 **G4 semi-quantitative load and cycle threshold values, using a threshold for specificity of 70%.**

| Sputum Xpert G4 result | n | CRP | | Xpert-MTB-HR | |
|------------------------|-----|----------|------------------|--------------|------------------|
| | | Positive | % Sens. (95% CI) | Positive | % Sens. (95% CI) |
| Semi-quantitative load | | | | | |
| Negative/Very Low | 29 | 13 | 44.8 (26.4-64.3) | 20 | 69.0 (49.2-84.7) |
| Low | 28 | 21 | 75.0 (55.1-89.3) | 22 | 78.6 (59.0-91.7) |
| Medium/High | 31 | 28 | 90.3 (74.2-98.0) | 30 | 96.8 (83.3-99.9) |
| Cycle threshold | | | | | |
| ≥28.0 | 31 | 15 | 48.4 (30.2-66.9) | 21 | 67.7 (48.6-83.3) |
| <28.0 | 57 | 47 | 82.5 (70.1-91.3) | 51 | 89.5 (78.5-96.0) |
| All confirmed cases* | 100 | 72 | 72.0 (62.1-80.5) | 82 | 82.0 (73.1-89.0) |

456 CRP, C-reactive protein. CI, confidence interval. *Includes 4 culture-confirmed TB cases in whom Xpert
457 semi-quantitative load was not available and 8 cases confirmed by Xpert Ultra.

458 **Table A1. Specificity at fixed sensitivity values, and sensitivity at fixed specificity values for CRP**
459 **and Xpert-MTB-HR.**

| Sensitivity | Specificity | | Sensitivity | | |
|-------------|-------------|--------------|-------------|------|--------------|
| | CRP | Xpert-MTB-HR | Specificity | CRP | Xpert-MTB-HR |
| 0.70 | 0.74 | 0.80 | 0.70 | 0.73 | 0.81 |
| 0.75 | 0.67 | 0.78 | 0.75 | 0.69 | 0.78 |
| 0.80 | 0.56 | 0.73 | 0.80 | 0.65 | 0.70 |
| 0.85 | 0.42 | 0.62 | 0.85 | 0.61 | 0.64 |
| 0.90 | 0.28 | 0.53 | 0.90 | 0.58 | 0.57 |
| 0.95 | 0.14 | 0.36 | 0.95 | 0.51 | 0.48 |

460 CRP: C-reactive protein. Values were obtained from 5,000 bootstrap replicates.

461 **Figure Legends**

462 **Figure 1. Flow diagram of study participants in mass screening and selection for**
463 **diagnostic accuracy sub-study.**

464 **Figure 2. Distribution of C-reactive protein concentrations and Xpert MTB-HR scores**
465 **among TB cases and controls.** Box-plots comparing the distributions of C-reactive protein
466 (top) and Xpert MTB-HR scores (bottom) between TB cases and control. CRP: C-reactive
467 protein.

468 **Figure 3. Correlation between C-reactive protein concentration and Xpert-MTB-HR**
469 **Score among TB cases and controls, with fitted linear regression lines.** Each dot indicates
470 a patient observation. Black line indicates linear regression for controls and blue line
471 indicates linear regression for cases, with shading indicating 95% confidence intervals. CRP:
472 C-reactive protein.

473 **Figure 4. Receiver operating characteristic curves for point-of-care C-reactive protein**
474 **and the Xpert MTB-HR assay.** AUC: Area under the curve. CRP: C-reactive protein.

475 **Figure 5. C-reactive protein and Xpert MTB-HR scores stratified by sputum Xpert**
476 **semi-quantitative values (A) and cycle thresholds (B).** Xpert negative, culture positive
477 individuals (“Negative”) and Xpert- and culture-negative controls (“Control”) are depicted.
478 CRP: C-reactive protein.




Figure 1






Figure 2






Figure 4




Figure 5a

